Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 27
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

  • Ayala Díaz, Rosa María
  • Martínez López, Joaquín
This phase Ib, non-randomized, open-label study evaluates the safety and tolerability of ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib-resistant myelofibrosis (MF). A total of 15 patients with primary or secondary MF received the study treatment; 13 patients had received prior ruxolitinib treatment (86.7%). Eight patients completed seven cycles (53.3%) and six patients completed twelve cycles of treatment (40%). All the patients experienced at least one adverse event (AE) during the study (the most common AEs were hyperglycemia, asthenia, and thrombocytopenia), and 14 patients registered at least one treatment-related AE (the most common treatment-related AEs were hyperglycemia (22.2%; three grade 3 cases). Five treatment-related serious AEs (SAEs) were reported in two patients (13.3%). No deaths were registered throughout the study. No dose-limiting toxicity was observed. Four out of fifteen (27%) patients experienced a 100% spleen size reduction at Cycle 7, and two additional patients achieved a >50% spleen size reduction, representing an overall response rate of 40% at Cycle 7. In conclusion, the tolerability of this combination was acceptable, and hyperglycemia was the most frequent treatment-related AE. Ruxolitinib in combination with nilotinib and prednisone showed relevant clinical activity in patients with MF. This trial was registered with EudraCT Number 2016-005214-21.
Repisalud
Publication Artículo científico (JournalArticle)

Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers

  • Casado, Concepcion
  • Marrero-Hernández, Sara
  • Márquez-Arce, Daniel
  • Pernas, Maria
  • Marfil, Silvia
  • Borràs-Grañana, Ferran
  • Olivares, Isabel
  • Cabrera-Rodríguez, Romina
  • Valera, María-Soledad
  • de Armas-Rillo, Laura
  • Lemey, Philippe
  • Blanco, Julià
  • Valenzuela-Fernández, Agustín
  • Lopez-Galindez, Luis Cecilio
A small group of HIV-1-infected individuals, called long-term nonprogressors (LTNPs), and in particular a subgroup of LTNPs, elite controllers (LTNP-ECs), display permanent control of viral replication and lack of clinical progression. This control is the result of a complex interaction of host, immune, and viral factors. We identified, by phylogenetic analysis, a cluster of LTNP-ECs infected with very similar low-replication HIV-1 viruses, suggesting the contribution of common viral features to the clinical LTNP-EC phenotype. HIV-1 envelope (Env) glycoprotein mediates signaling and promotes HIV-1 fusion, entry, and infection, being a key factor of viral fitness in vitro, cytopathicity, and infection progression in vivo Therefore, we isolated full-length env genes from viruses of these patients and from chronically infected control individuals. Functional characterization of the initial events of the viral infection showed that Envs from the LTNP-ECs were ineffective in the binding to CD4 and in the key triggering of actin/tubulin-cytoskeleton modifications compared to Envs from chronic patients. The viral properties of the cluster viruses result in a defective viral fusion, entry, and infection, and these properties were inherited by every virus of the cluster. Therefore, inefficient HIV-1 Env functions and signaling defects may contribute to the low viral replication capacity and transmissibility of the cluster viruses, suggesting a direct role in the LTNP-EC phenotype of these individuals. These results highlight the important role of viral characteristics in the LTNP-EC clinical phenotype. These Env viral properties were common to all the cluster viruses and thus support the heritability of the viral characteristics.IMPORTANCE HIV-1 long-term nonprogressor elite controller patients, due to their permanent control of viral replication, have been the object of numerous studies to identify the factors responsible for this clinical phenotype. In this work, we analyzed the viral characteristics of the envelopes of viruses from a phylogenetic cluster of LTNP-EC patients. These envelopes showed ineffective binding to CD4 and the subsequent signaling activity to modify actin/tubulin cytoskeletons, which result in low fusion and deficient entry and infection capacities. These Env viral characteristics could explain the nonprogressor clinical phenotype of these patients. In addition, these inefficient env viral properties were present in all viruses of the cluster, supporting the heritability of the viral phenotype.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Identification of relevant features using SEQENS to improve supervised machine learning models predicting AML treatment outcome

  • Pons-Suñer, Pedro
  • Signol, François
  • Alvarez, Noemi
  • Sargas, Claudia
  • Dorado, Sara
  • Gil Ortí, Jose Vicente
  • Delgado Sanchis, Juan A.
  • Llop, Marta
  • Arnal, Laura
  • Ayala, Rosa
  • Barragán, Eva
  • Llobet Azpitarte, Rafael|||0000-0002-8278-9740
  • Perez-Cortes, Juan-Carlos|||0000-0001-6506-090X
[EN] Background and objective: This study has two main objectives. First, to evaluate a feature selection methodology based on SEQENS, an algorithm for identifying relevant variables. Second, to validate machine learning models that predict the risk of complications in patients with acute myeloid leukemia (AML) using data available at diagnosis. Predictions are made at three time points: 90 days, six months, and one year post-diagnosis. These objectives represent fundamental steps toward the development of a tool to assist clinicians in therapeutic decision-making and provide insights into the risk factors associated with AML complications. Methods: A dataset of 568 patients, including demographic, clinical, genetic (VAF), and cytogenetic information, was created by combining data from Hospital 12 de Octubre (Madrid, Spain) and Instituto de Investigación Sanitaria La Fe (Valencia, Spain). Feature selection based on an enhanced version of SEQENS was conducted for each time point, followed by the comparison of four classifiers (XGBoost, Multi-Layer Perceptron, Logistic Regression and Decision Tree) to assess the impact of feature selection on model performance. Results: SEQENS identified different relevant features for each prediction horizon, with Age, TP53, - 7/7Q, and EZH2 consistently relevant across all time points. The models were evaluated using 5-fold cross-validation, XGBoost achieve the highest average ROC-AUC scores of 0.81, 0.84, and 0.82 for 90-day, 6-month, and 1-year predictions, respectively. Generally, performance remained stable or improved after applying SEQENS-based feature selection. Evaluation on an external test set of 54 patients yielded ROC-AUC scores of 0.72 (90-day), 0.75 (6-month), and 0.68 (1-year). Conclusions: The models achieved performance levels that suggest they could serve as therapeutic decision support tools at different times after diagnosis. The selected variables align with the European LeukemiaNet (ELN) 2022 risk classification, and the SEQENS-based feature selection effectively reduced the feature set while maintaining prediction accuracy., The publication of this article has been funded by the Generalitat Valenciana through IVACE (Valencian Institute of Business Competitiveness, https://www.ivace.es/index.php/es/) under project number IMAMCA/2025/11. This work has been supported by the Instituto de Salud Carlos III (ISCIII) through projects PI19/00730, PI19/01518 and PI22/1088, by the Instituto de Investigacion Hospital 12 de Octubre (imas12), by the Generalitat Valenciana through IVACE and by the European Union through FEDER funding under project IMDEEA/2023/92.
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

  • Usai, Carla
  • Ainsua-Enrich, Erola
  • Urrea Gales, Victor
  • Pradenas, Edwards
  • Lorca-Oró, Cristina
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Carabelli, Julieta
  • Trinité, Benjamin
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Izquierdo-Useros, Nuria
  • Clotet, Bonaventura
  • Blanco, Julià
  • Guallar, Victor
  • Cantero Portillo, Guillermo
  • Serra Gironella, Joan
  • Carrillo, Jorge
  • Segalés, Joaquim
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation., This work was partly supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CAN was supported by predoctoral grants from Generalitat de Catalunya (2020 FI_B_0742; 2022 FI_B_00698). EPwas supportedbyadoctoralgrant from the National Agency for Research and Development of Chile (ANID: 72180406). NIU is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real-time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope and an ÄKTA Go protein purification system. Graphical abstract and drawing in Figs. 1 and 4 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Guallar, Victor
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Carrillo, Jorge
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18- hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development., This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452 to B.C.; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 to J.C. and SLD0016 to J.B.), the Carlos III Health Institute (PI17/ 01518 to J.B. and PI18/01332 to J.C.). J.B. is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). In addition, the project was also supported by the crowdfunding projects “YomeCorono” (to A.V., V.G., J.C., B.C., J.B. and N.I.-U.), BonPreu/Esclat, and Correos (to J.B.). CAN was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742). A.P.G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B_00698). P.A.R. was funded by a predoctoral fellowship from the Government of Catalonia (2020FI_B2_00138). E.P. was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021- CORONA-01 (grant 101046118). This study was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope, and an ÄKTA go protein purification system. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We thank to Ismael Valera, the CMCiB’s staff (Sara Capdevila, Jordi Grifols, Rosa Maria Ampudia, Jorge Diaz, Yaiza Rosales and Sergi Sunye) and the BSL3 IRTA-CReSA staff (Xavier Abad, Ivan Cordon, Anna Pou, Oscar García, Joanna Wiacek, Maria Angeles Osuna, Luís Ribas and Claudia Pereira Sunyé) for their technical assistance with in vivo animal studies., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola
  • Pedreño-Lopez, Núria
  • Bracke, Carmen
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pradenas, Edwards
  • Trinité, Benjamin
  • Marfil, Silvia
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana
  • Escribà, Tuixent
  • Jimenez-Moyano, Esther
  • Peña, Ruth
  • Cedeño, Samandhy
  • Prado, Julia G.
  • Mothe, Beatriz
  • Brander, Christian
  • Izquierdo-Useros, Nuria
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Massanella, Marta
  • Benitez, Rosa María
  • Romero, Alba
  • Molina-Morant, Daniel
  • Blanco, Julià
  • Clotet, Bonaventura
  • Mateu, Lourdes
  • Pedro-Botet, María Luisa
  • Carrillo, Jorge
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Carabelli, Julieta
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Clotet, Bonaventura
  • Guallar, Victor
  • Segalés, Joaquim
  • Carrillo, Jorge
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S- 29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/ Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CÁ-N, AP-G, and PA-R were supported by predoctoral grants from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742; 2022 FI_B_00698 and 2020FI_B2_00138, respectively). EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The JAK2 46/1 haplotype influences PD-L1 expression

  • Carreño-Tarragona, Gonzalo
  • Tiana, María
  • Rouco, Raquel
  • Leivas, Alejandra
  • Victorino, Jesús
  • García-Vicente, Roberto
  • Chase, Andrew J.
  • Maidana, Andrea
  • Tapper, William J.
  • Ayala, Rosa
  • Cross, Nicholas C. P.
  • Martínez-López, Joaquín
  • Manzanares, Miguel
Although described more than a decade ago, the mechanism by which the JAK2 46/1 haplotype increases the risk of developing JAK2-mutated myeloproliferative neoplasms (MPNs) remains unexplained. Inflammation and immunity are linked to MPN development and thus could be relevant to the mechanism by which 46/1 mediates its effect. Here, we show that programmed death-1 receptor ligand (PD-L1) expression is elevated in 46/1 haplotype, both in healthy carriers and in CD34 cells from patients with MPN. Using circular chromosome conformation capture, we observed that PD-L1 and the neighboring PD-L2 loci physically interact with JAK2 in a manner that differs between 46/1 and nonrisk haplotypes. CRISPR/Cas9 genome editing identified a region within JAK2 intron 2 that influences both JAK2 and PD-L1 expression. We suggest that increased PD-L1 expression may be relevant to the mechanism by which 46/1 leads to an increased inherited risk of developing MPN., This study was funded by the Asociacion Española Contra el Cáncer (AECC) Ideas Semilla AECC 2017 grants PID2020-115755GB-I00 and PID2023-151742NB-I00 (funded by Ministerio de Ciencia, Innovacion y Universidades /Agencia Estatal de Investigación [AEI]/10.13039/ 501100011033); by the Subdireccion General de Investigación Sanitaria ´ (Instituto de Salud Carlos III, Spain) grant PI19/01518; by the Cancer Research Innovation in Science (CRIS) Against Cancer Foundation grant 2018/001; and by the Instituto de Investigacion Hospital 12 de Octubre (IMAS12). CBM is supported by an institutional grant from the Fundacion Ramón Areces and Severo Ochoa Center of Excellence (grant CEX2021-001154-S, funded by Ministerio de Ciencia e Innovacion /AEI/10.13039/501100011033).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Carabelli, Julieta
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Clotet, Bonaventura
  • Guallar, Victor
  • Segalés, Joaquim
  • Carrillo, Jorge
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S- 29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/ Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CÁ-N, AP-G, and PA-R were supported by predoctoral grants from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742; 2022 FI_B_00698 and 2020FI_B2_00138, respectively). EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola
  • Pedreño-Lopez, Núria
  • Bracke, Carmen
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pradenas, Edwards
  • Trinité, Benjamin
  • Marfil, Silvia
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana
  • Escribà, Tuixent
  • Jimenez-Moyano, Esther
  • Peña, Ruth
  • Cedeño, Samandhy
  • Prado, Julia G.
  • Mothe, Beatriz
  • Brander, Christian
  • Izquierdo-Useros, Nuria
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Massanella, Marta
  • Benitez, Rosa María
  • Romero, Alba
  • Molina-Morant, Daniel
  • Blanco, Julià
  • Clotet, Bonaventura
  • Mateu, Lourdes
  • Pedro-Botet, María Luisa
  • Carrillo, Jorge
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

  • Usai, Carla
  • Ainsua-Enrich, Erola
  • Urrea Gales, Victor
  • Pradenas, Edwards
  • Lorca-Oró, Cristina
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Carabelli, Julieta
  • Trinité, Benjamin
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Izquierdo-Useros, Nuria
  • Clotet, Bonaventura
  • Blanco, Julià
  • Guallar, Victor
  • Cantero Portillo, Guillermo
  • Serra Gironella, Joan
  • Carrillo, Jorge
  • Segalés, Joaquim
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29 protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation. Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion and production of neutralising antibodies; however, animals were only partially protected from weight loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while tissue lesion development was not altered. In GSH, the shortest interval between immunisation and inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29 efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine efficacy in older animals as part of preclinical vaccine evaluation., This work was partly supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 and SLD0016), the Carlos III Health Institute (PI17/01518 and PI18/01332), and the crowdfunding projects “YomeCorono”, BonPreu/Esclat, and Correos. JB is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). CAN was supported by predoctoral grants from Generalitat de Catalunya (2020 FI_B_0742; 2022 FI_B_00698). EPwas supportedbyadoctoralgrant from the National Agency for Research and Development of Chile (ANID: 72180406). NIU is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118). This study was also supported by CIBER - Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real-time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope and an ÄKTA Go protein purification system. Graphical abstract and drawing in Figs. 1 and 4 were created with BioRender.com., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Ávila-Nieto, Carlos
  • Serra Gironella, Joan
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola
  • Brustolin, Marco
  • Rodríguez de la Concepción, María Luisa
  • Pedreño-Lopez, Núria
  • Rodon, Jordi
  • Urrea, Victor
  • Pradenas, Edwards
  • Marfil, Silvia
  • Ballana, Ester
  • Riveira-Muñoz, Eva
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran
  • Cantero, Guillermo
  • Pons-Grífols, Anna
  • Rovirosa, Carla
  • Aguilar-Gurrieri, Carmen
  • Ortiz, Raquel
  • Barajas, Ana
  • Trinité, Benjamin
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana
  • Perez-Zsolt, Daniel
  • Izquierdo-Useros, Nuria
  • Valencia, Alfonso
  • Blanco, Julià
  • Guallar, Victor
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Carrillo, Jorge
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18- hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development., This work was supported by Grifols pharmaceutical, the CERCA Program (2021 SGR 00452 to B.C.; Generalitat de Catalunya), Direcció General de Recerca i Innovació en Salut (Generalitat de Catalunya) (projects SLD0015 to J.C. and SLD0016 to J.B.), the Carlos III Health Institute (PI17/ 01518 to J.B. and PI18/01332 to J.C.). J.B. is supported by the Health Department of the Catalan Government (Generalitat de Catalunya). In addition, the project was also supported by the crowdfunding projects “YomeCorono” (to A.V., V.G., J.C., B.C., J.B. and N.I.-U.), BonPreu/Esclat, and Correos (to J.B.). CAN was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2020 FI_B_0742). A.P.G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B_00698). P.A.R. was funded by a predoctoral fellowship from the Government of Catalonia (2020FI_B2_00138). E.P. was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID: 72180406). N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021- CORONA-01 (grant 101046118). This study was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red (CB 2021), Carlos III Health Institute, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU. We would like to thank Foundation Dormeur that support the acquisition of the QuantStudio-5 real time PCR system, an Eclipse Ts2R-FL Inverted Research Microscope, and an ÄKTA go protein purification system. Funders had no role in study design, data analysis, decision to publish, or manuscript preparation. We thank to Ismael Valera, the CMCiB’s staff (Sara Capdevila, Jordi Grifols, Rosa Maria Ampudia, Jorge Diaz, Yaiza Rosales and Sergi Sunye) and the BSL3 IRTA-CReSA staff (Xavier Abad, Ivan Cordon, Anna Pou, Oscar García, Joanna Wiacek, Maria Angeles Osuna, Luís Ribas and Claudia Pereira Sunyé) for their technical assistance with in vivo animal studies., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The geometry of the real planar polynomial differential systems having their orbits imbedded in conics

  • Llibre, Jaume|||0000-0002-9511-5999
  • Mahdi, Adam
  • Roé Vellvé, Joaquim|||0000-0003-0033-8442
We classify and provide the global phase portraits in the Poincaré disc of all real planar polynomial differential systems having their orbits embedded in conics. This is achieved via the real affine classification of the pencils of conics. All such polynomial vector fields have degree less than or equal to 3. Also, when the degree is three, infinity is filled with singular points.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

  • Trinité, Benjamin|||0000-0003-3809-042X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Rodon, Jordi|||0000-0002-1032-9091
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Urrea, Víctor|||0000-0002-2577-856X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Avila-Nieto, Carlos
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Paredes, Roger|||0000-0002-6553-691X
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Guallar, Victor|||0000-0002-4580-1114
  • Ruiz, Lidia
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Massanella, Marta|||0000-0002-3326-151X
  • Puig, Jordi|||0000-0002-4075-0346
  • Chamorro, Anna
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Blanco, Julià|||0000-0002-2225-0217
The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity. Between March and May 2020, the prospective KING study enrolled 72 COVID-19+ participants grouped according to disease severity. SARS-CoV-2 infection was diagnosed by serological and virological tests. Plasma neutralizing responses were assessed against replicative virus and pseudoviral particles. Multiple regression and non-parametric tests were used to analyze dependence of parameters. The magnitude of neutralizing titers significantly increased with disease severity. Hospitalized individuals developed higher titers compared to mild-symptomatic and asymptomatic individuals, which together showed titers below the detection limit in 50% of cases. Longitudinal analysis confirmed the strong differences in neutralizing titers between non-hospitalized and hospitalized participants and showed rapid kinetics of appearance of neutralizing antibodies (50% and 80% of maximal activity reached after 11 and 17 days after symptoms onset, respectively) in hospitalized patients. No significant impact of age, gender or treatment on the neutralizing titers was observed in this limited cohort. These data identify a clear association of humoral immunity with disease severity and point to immune mechanisms other than antibodies as relevant players in COVID-19 protection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

  • Ayala, Rosa|||0000-0002-2699-8353
  • Rapado, Inmaculada
  • Onecha, Esther
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Algarra Algarra, Jesus Lorenzo
  • Tormo, Mar|||0000-0001-9622-1649
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Herrera, Pilar|||0000-0002-4118-7110
  • Ramos, Fernando
  • Salamero, Olga|||0000-0003-3237-0025
  • Lavilla, Esperanza|||0000-0003-1490-0678
  • Gil, Cristina
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Vidriales, María Belén|||0000-0001-5049-3673
  • Labrador, Jorge|||0000-0002-3696-0287
  • Falantes, José Francisco|||0000-0001-8660-7038
  • Sayas, María José
  • Paiva, Bruno|||0000-0003-1977-3815
  • Barragán, Eva
  • Prosper, Felipe|||0000-0001-6115-8790
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Montesinos, Pau|||0000-0002-3275-5593
Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10 -7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Urrea, Víctor|||0000-0002-2577-856X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Rodon, Jordi|||0000-0002-1032-9091
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Guallar, Victor|||0000-0002-4580-1114
  • Lepore, Rosalba
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Trujillo, Glòria
  • Trapé, Jaume
  • González-Fernández, Carolina
  • Flor, Antonia
  • Pérez-Vidal, Rafel
  • Toledo, Ruth
  • Chamorro, Anna
  • Paredes, Roger|||0000-0002-6553-691X
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Massanella, Marta|||0000-0002-3326-151X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
With the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to assess the protection conferred by both previous infections and current vaccination. Here we tested the neutralizing activity of infected and/or vaccinated individuals against pseudoviruses expressing the spike of the original SARS-CoV-2 isolate Wuhan-Hu-1 (WH1), the D614G mutant and the B.1.1.7 variant. Our data show that parameters of natural infection (time from infection and nature of the infecting variant) determined cross-neutralization. Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant compared to both the WH1 strain and the D614G mutant. Interestingly, upon vaccination, previously infected individuals developed more robust neutralizing responses against B.1.1.7, suggesting that vaccines can boost the neutralization breadth conferred by natural infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Rodon, Jordi|||0000-0002-1032-9091
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Guallar, Victor|||0000-0002-4580-1114
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Paredes, Roger|||0000-0002-6553-691X
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Chamorro, Anna
  • Toledo, Ruth
  • Massanella, Marta|||0000-0002-3326-151X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Romero-Durana, Miguel|||0000-0001-6779-8553
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Avila-Nieto, Carlos
  • Pérez, Mónica
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Andrés, Cristina|||0000-0002-3200-0895
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Guallar, Victor|||0000-0002-4580-1114
  • Lepore, Rosalba
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Urrea, Víctor|||0000-0002-2577-856X
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Blanco, Julià|||0000-0002-2225-0217
The emerging SARS-CoV-2 variants of concern (VOCs) may display enhanced transmissibility, more severity and/or immune evasion; however, the pathogenesis of these new VOCs in experimental SARS-CoV-2 models or the potential infection of other animal species is not completely understood. Here we infected K18-hACE2 transgenic mice with B.1, B.1.351/Beta, B.1.617.2/Delta and BA.1.1/Omicron isolates and demonstrated heterogeneous infectivity and pathogenesis. B.1.351/Beta variant was the most pathogenic, while BA.1.1/Omicron led to lower viral RNA in the absence of major visible clinical signs. In parallel, we infected wildtype (WT) mice and confirmed that, contrary to B.1 and B.1.617.2/Delta, B.1.351/Beta and BA.1.1/Omicron can infect them. Infection in WT mice coursed without major clinical signs and viral RNA was transient and undetectable in the lungs by day 7 post-infection. In silico modeling supported these findings by predicting B.1.351/Beta receptor binding domain (RBD) mutations result in an increased affinity for both human and murine ACE2 receptors, while BA.1/Omicron RBD mutations only show increased affinity for murine ACE2.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection, A Case Report

  • Massanella, Marta|||0000-0002-3326-151X
  • Martin-Urda, Anabel
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Marín, Toni
  • Aldas Criado, Irene|||0000-0001-9291-873X
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Kipelainen, Athina
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Avila-Nieto, Carlos
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Rodon, Jordi|||0000-0002-1032-9091
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Parera, Mariona|||0000-0002-0756-8307
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Prado, Julia G.|||0000-0002-5439-4645
  • Ballana, Ester|||0000-0002-5215-7363
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Masabeu, Àngels
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Toda, Maria de la Roca
  • Paredes, Roger|||0000-0002-6553-691X
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections have been reported; however, most cases are milder than the primary infection. We report the first case of a life-threatening critical presentation of a SARS-CoV-2 reinfection. A 62-year-old man from Palamós (Spain) suffered a first mild coronavirus disease 2019 (COVID-19) episode in March 2020, confirmed by 2 independent SARS-CoV-2 nasopharyngeal polymerase chain reaction (PCR) assays and a normal radiograph. He recovered completely and tested negative on 2 consecutive PCRs. In August 2020, the patient developed a second SARS-CoV-2 infection with life-threatening bilateral pneumonia and Acute respiratory distress syndrome criteria, requiring COVID-19-specific treatment (remdesivir + dexamethasone) plus high-flow oxygen therapy. Nasopharyngeal swabs from the second episode were obtained for virus quantification by real-time PCR, for virus outgrowth and sequencing. In addition, plasma and peripheral blood mononuclear cells during the hospitalization period were used to determine SARS-CoV-2-specific humoral and T-cell responses. Genomic analysis of SARS-CoV-2 showed that the virus had probably originated shortly before symptom onset. When the reinfection occurred, the subject showed a weak immune response, with marginal humoral and specific T-cell responses against SARS-CoV-2. All antibody isotypes tested as well as SARS-CoV-2 neutralizing antibodies increased sharply after day 8 postsymptoms. A slight increase of T-cell responses was observed at day 19 after symptom onset. The reinfection was firmly documented and occurred in the absence of robust preexisting humoral and cellular immunity. SARS-CoV-2 immunity in some subjects is unprotective and/or short-lived; therefore, SARS-CoV-2 vaccine schedules inducing long-term immunity will be required to bring the pandemic under control.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Bracke Manzanares, Carmen|||0000-0002-0306-8321
  • Avila-Nieto, Carlos
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana|||0000-0002-2219-8826
  • Escribà, Tuixent|||0000-0001-9467-7802
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Peña, Ruth
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Prado, Julia G.|||0000-0002-5439-4645
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Massanella, Marta|||0000-0002-3326-151X
  • Benítez Díaz, Rosa María|||0000-0001-6972-6094
  • Romero, Alba
  • Molina-Morant, Daniel|||0000-0002-4102-1065
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Pedro Botet, Maria Luisa|||0000-0001-7252-3191
  • Carrillo, Jorge|||0000-0003-0221-5948
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n=9), common variable immunodeficiency (CVID, n=12), combined immunodeficiency (CID, n=1), and thymoma with immunodeficiency (TID, n=1). unPAD patients and healthy controls (HCs, n=10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Interestingly, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+ T cells. CID and TID patients developed cellular but not humoral responses. While the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Urrea, Víctor|||0000-0002-2577-856X
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Blanco, Pau
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Molinos-Albert, Luis Manuel|||0000-0001-5447-6803
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Avila-Nieto, Carlos
  • Varela, Ismael|||0000-0002-3825-372X
  • Cervera Gracia, Laura|||0000-0002-3639-2793
  • Gutiérrez-Granados, Sònia
  • Segura, Maria Mercedes
  • Gòdia, Francesc|||0000-0002-4060-9887
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered to maximise the presence of antigen on the VLP surface. An HIV-1 gp41-derived protein (Min), including the C-terminal part of gp41 and the transmembrane domain, was fused to HIV-1 Gag. This resulted in high-density MinGag-VLPs. These VLPs demonstrated to be highly immunogenic in animal models using either a homologous (VLP) or heterologous (DNA/VLP) vaccination regimen, with the latter yielding 10-fold higher anti-Gag and anti-Min antibody titres. Despite these strong humoral responses, immunisation with MinGag-VLPs did not induce neutralising antibodies. Nevertheless, antibodies were predominantly of an IgG2b/IgG2c profile and could efficiently bind CD16-2. Furthermore, we demonstrated that MinGag-VLP vaccination could mediate a functional effect and halt the progression of a Min-expressing tumour cell line in an in vivo mouse model.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Syphilis vaccine, challenges, controversies and opportunities

  • Avila-Nieto, Carlos
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
  • Carrillo, Jorge|||0000-0003-0221-5948
Syphilis is a sexually or vertically (mother to fetus) transmitted disease caused by the infection of Treponema pallidum subspecie pallidum (TPA). The incidence of syphilis has increased over the past years despite the fact that this bacterium is an obligate human pathogen, the infection route is well known, and the disease can be successfully treated with penicillin. As complementary measures to preventive campaigns and early treatment of infected individuals, development of a syphilis vaccine may be crucial for controlling disease spread and/or severity, particularly in countries where the effectiveness of the aforementioned measures is limited. In the last century, several vaccine prototypes have been tested in preclinical studies, mainly in rabbits. While none of them provided protection against infection, some prototypes prevented bacteria from disseminating to distal organs, attenuated lesion development, and accelerated their healing. In spite of these promising results, there is still some controversy regarding the identification of vaccine candidates and the characteristics of a syphilis-protective immune response. In this review, we describe what is known about TPA immune response, and the main mechanisms used by this pathogen to evade it. Moreover, we emphasize the importance of integrating this knowledge, in conjunction with the characterization of outer membrane proteins (OMPs), to expedite the development of a syphilis vaccine that can protect against TPA infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

  • Trigueros Peña, Macedonia|||0000-0003-4156-1018
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Palacín, Dolors
  • Muñoz-López, Francisco|||0000-0003-1789-1658
  • Avila-Nieto, Carlos
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Isnard, Mar|||0000-0001-6297-8520
  • Moreno, Nemesio|||0000-0002-1617-9549
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Puig Oliva, Teresa
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Chamorro, Anna
  • Martinez, Ana
  • Toledo, Ruth
  • Font, Marta
  • Ara del Rey, Jordi|||0000-0002-7281-9969
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Prat, Nuria
  • Massanella, Marta|||0000-0002-3326-151X
SARS-CoV-2 vaccination is the most effective strategy to protect older residents of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses are less effective in older adults. Here, we characterised the humoral responses of institutionalised seniors 3 months after they had received the mRNA/BNT162b2 vaccine. plasma levels of SARS-CoV-2-specific total IgG, IgM and IgA antibodies were measured before and 3 months after vaccination in older residents of LTCF. Neutralisation capacity was assessed in a pseudovirus neutralisation assay against the original WH1 and later B.1.617.2/Delta variants. A group of younger adults was used as a reference group. three months after vaccination, uninfected older adults presented reduced SARS-CoV-2-specific IgG levels and a significantly lower neutralisation capacity against the WH1 and Delta variants compared with vaccinated uninfected younger individuals. In contrast, COVID-19-recovered older adults showed significantly higher SARS-CoV-2-specific IgG levels after vaccination than their younger counterparts, whereas showing similar neutralisation activity against the WH1 virus and an increased neutralisation capacity against the Delta variant. Although, similarly to younger individuals, previously infected older adults elicit potent cross-reactive immune responses, higher quantities of SARS-CoV-2-specific IgG antibodies are required to reach the same neutralisation levels. although hybrid immunity seems to be active in previously infected older adults 3 months after mRNA/BNT162b2 vaccination, humoral immune responses are diminished in COVID-19 uninfected but vaccinated older residents of LTCF. These results suggest that a vaccine booster dose should be prioritised for this particularly vulnerable population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Guallar, Victor|||0000-0002-4580-1114
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The introduction of the K986P and V987P (S-2P) mutations increases the production and immunogenicity of the recombinant S trimer, suggesting that these two parameters are related. Nevertheless, S-2P still shows some molecular instability and it is produced with low yield. Here we described a novel set of mutations identified by molecular modeling and located in the S2 region of the S-2P that increase its production up to five-fold. Besides their immunogenicity, the efficacy of two representative S-2P-based mutants, S-29 and S-21, protecting from a heterologous SARS-CoV-2 Beta variant challenge was assayed in K18-hACE2 mice (an animal model of severe SARS-CoV-2 disease) and golden Syrian hamsters (GSH) (a moderate disease model). S-21 induced higher level of WH1 and Delta variants neutralizing antibodies than S-2P in K18-hACE2 mice three days after challenge. Viral load in nasal turbinate and oropharyngeal samples were reduced in S-21 and S-29 vaccinated mice. Despite that, only the S-29 protein protected 100% of K18-hACE2 mice from severe disease. When GSH were analyzed, all immunized animals were protected from disease development irrespectively of the immunogen they received. Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S-29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Guallar, Victor|||0000-0002-4580-1114
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development. In this study, the authors report a mutation that increases the production of recombinant SARS-CoV-2 Spike and exposure of the RBD. In animal models, a Spike-based vaccine containing the mutation induces strong immunogenicity, provides protection from disease and results in faster tissue viral clearance.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA registry study

  • Ayala, Rosa
  • Carreño-Tarragona, Gonzalo
  • Barragán, Eva
  • Boluda, Blanca
  • Larráyoz, María José
  • Chillón, María Carmen
  • Carrillo-Cruz, Estrella
  • Bilbao, Cristina
  • Sánchez-García, Joaquín
  • Bernal del Castillo, Teresa
  • Martínez-Cuadrón, David
  • Gil, Cristina
  • Serrano, Josefina
  • Rodríguez-Medina, Carlos
  • Bergua, Juan
  • Pérez-Simón, José A.
  • Calbacho, María
  • Alonso-Domínguez, Juan M.
  • Labrador, Jorge
  • Tormo, Mar
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Rapado, Inmaculada
  • Sargas, Claudia
  • Vázquez Urio, Iria
  • Calasanz, María José
  • Gómez-Casares, Teresa
  • García-Sanz, Ramón
  • Sanz, Miguel A.
  • Martínez-López, Joaquín
  • Montesinos, Pau
FLT3-ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains controversial. Our study focuses on the prognostic impact of FLT3-ITD and its ratio in a series of 2901 adult patients treated intensively in the pre-FLT3 inhibitor era and reported in the PETHEMA registry. A total of 579 of these patients (20%) harbored FLT3-ITD mutations. In multivariate analyses, patients with an FLT3-ITD allele ratio (AR) of >0.5 showed a lower complete remission (CR rate) and OS (HR 1.47, p = 0.009), while AR > 0.8 was associated with poorer RFS (HR 2.1; p < 0.001). Among NPM1/FLT3-ITD-mutated patients, median OS gradually decreased according to FLT3-ITD status and ratio (34.3 months FLT3-ITD-negative, 25.3 months up to 0.25, 14.5 months up to 0.5, and 10 months ≥ 0.5, p < 0.001). Post-remission allogeneic transplant (allo-HSCT) resulted in better OS and RFS as compared to auto-HSCT in NPM1/FLT3-ITD-mutated AML regardless of pre-established AR cutoff (≤0.5 vs. >0.5). Using the maximally selected log-rank statistics, we established an optimal cutoff of FLT3-ITD AR of 0.44 for OS, and 0.8 for RFS. We analyzed the OS and RFS according to FLT3-ITD status in all patients, and we found that the group of FLT3-ITD-positive patients with AR < 0.44 had similar 5-year OS after allo-HSCT or auto-HSCT (52% and 41%, respectively, p = 0.86), but worse RFS after auto-HSCT (p = 0.01). Among patients with FLT3-ITD AR > 0.44, allo-HSCT was superior to auto-HSCT in terms of OS and RFS. This study provides more evidence for a better characterization of patients with AML harboring FLT3-ITD mutations., We thank all patients for agreeing to participate in these studies. This study was funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01518 and PI19/00730 and co-funded by the European Union, the CRIS Against Cancer Foundation, grant 2018/001, and by the Instituto de Investigación Hospital 12 de Octubre (IMAS12). A complete list of the institutions and clinicians participating in the PETHEMA epidemiologic registry of acute myeloid leukemia and acute promyelocytic leukemia appears in the Supplementary Material.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

  • Simoes, Catia
  • Chillón, María Carmen
  • Martínez-Cuadrón, David
  • Calasanz, María José
  • Vridiales, María-Belén
  • Vázquez Urio, Iria
  • Hernández-Ruano, Montserrat
  • Ariceta, Beñat
  • Aguirre-Ruiz, Paula
  • Burgos, Leire
  • Alignani, Diego
  • Sarvide, Sarai
  • Villar, Sara
  • Alfonso Pierola, Ana
  • Prósper, Felipe
  • Ayala, Rosa
  • Martínez-López, Joaquín
  • Bergua Burgués, Juan Miguel
  • Vives, Susana
  • Pérez-Simón, José A.
  • García-Fortes, María
  • Bernal del Castillo, Teresa
  • Colorado, Mercedes
  • Olave, Mayte
  • Rodríguez-Gutiérrez, Juan I.
  • Labrador, Jorge
  • Gonzalez Díaz, Marcos
  • San-Miguel, Jesús F.
  • Sanz, Miguel A.
  • Montesinos, Pau
  • Paiva, Bruno David Lourenço
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, analyzed at the onset of AML using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct leukemogenesis. Dysplastic cells were detected by MFC in 285 of 348 (82%) newly diagnosed patients with AML. Presence of dysplasia according to MFC and World Health Organization criteria had no prognostic value in older adults. NGS of dysplastic cells and blasts isolated at diagnosis identified 3 evolutionary patterns: stable (n = 12 of 21), branching (n = 4 of 21), and clonal evolution (n = 5 of 21). In patients achieving complete response (CR), integrated MFC and FACS with NGS showed persistent measurable residual disease (MRD) in phenotypically normal cell types, as well as the acquisition of genetic traits associated with treatment resistance. Furthermore, whole-exome sequencing of dysplastic and leukemic cells at diagnosis and of MRD uncovered different clonal involvement in dysplastic myelo-erythropoiesis, leukemic transformation, and chemoresistance. Altogether, we showed that it is possible to reconstruct leukemogenesis in ~80% of patients with newly diagnosed AML, using techniques other than single-cell multiomics., This work was supported by grants from the Área de Oncología del Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red (CIBER-ONC) (CB16/12/00369, CB16/12/00233, CB16/12/ 00489, and CB16/12/00284), Instituto de Salud Carlos III/Sub-dirección General de Investigación Sanitaria (FIS numbers PI16/ 01661, PI16/00517, and PI19/01518), and the Plan de Investigación de la Universidad de Navarra (PIUNA 2014-18). This work was supported internationally by the Cancer Research UK, FCAECC, and AIRC under the Accelerator Award Program (EDITOR).